Synergistic effects of family history of hepatocellular carcinoma and hepatitis b virus infection on risk for incident hepatocellular carcinoma

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 12, 2013, Pages 1636-1645.e3

  Loomba, Rohit ^a   Liu, Jessica ^b   Yang, Hwai I ^b,c,d   Lee, Mei Hsuan ^b,e   Lu, Sheng Nan ^f   Wang, Li Yu ^g   Iloeje, Uchenna H ^h   You, San Lin ^b   Brenner, David ^a   Chen, Chien Jen ^b,i  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENOMICS RESEARCH CENTER   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^g MACKAY MEDICAL COLLEGE   (Taiwan)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Cancer Risk Factor; Cirrhosis; Epidemiology; Liver Disease

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; BODY MASS; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; FAMILY HISTORY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT;

AP; ATTRIBUTABLE PROPORTION; CANCER RISK FACTOR; CI; CIRRHOSIS; CONFIDENCE INTERVAL; EPIDEMIOLOGY; HAZARD RATIO; HBEAG; HBSAG; HBV; HCC; HEPATITIS B E ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS; HEPATOCELLULAR CARCINOMA; HR; LIVER DISEASE; RELATIVE EXCESS RISK CAUSED BY INTERACTION; RERI; REVEAL; RISK EVALUATION OF VIRAL LOAD ELEVATION AND ASSOCIATED LIVER DISEASE/CANCER-HEPATITIS B VIRUS; SI; SYNERGY INDEX;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FAMILY HEALTH; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RISK ASSESSMENT; TAIWAN;

EID: 84887821093     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.04.043     Document Type: Article

References (34)

1. Altekruse S.F., McGlynn K.A., Reichman M.E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. JClin Oncol 2009, 27:1485-1491.
2. The global burden of disease: 2004 update. Available at: ; WHO Press, October, 2008. Accessed 2011. http://www.who.int/evidence/bod.
3. Everhart J.E., Ruhl C.E. Burden of digestive diseases in the United States part III: liver, biliary tract, and pancreas. Gastroenterology 2009, 136:1134-1144.
4. El-Serag H.B., Davila J.A., Petersen N.J., et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003, 139:817-823.
5. Kim W.R., Gores G.J., Benson J.T., et al. Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology 2005, 129:486-493.
6. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. NEngl J Med 2008, 359:378-390.
7. Lopez P.M., Villanueva A., Llovet J.M. Systematic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006, 23:1535-1547.
8. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
9. McGlynn K.A., London W.T. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011, 15:223-243. vii-x.
10. Venook A.P., Papandreou C., Furuse J., et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010, 15(Suppl 4):5-13.
11. Yang H.I., Lu S.N., Liaw Y.F., et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. NEngl J Med 2002, 347:168-174.
12. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005, 25:143-154.
13. Lok A.S. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2004, 127:S303-S309.
14. Omata M., Lesmana L.A., Tateishi R., et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010, 4:439-474.
15. Mair R.D., Valenzuela A., Ha N.B., et al. Incidence of hepatocellular carcinoma among US patients with cirrhosis of viral or nonviral etiologies. Clin Gastroenterol Hepatol 2012, 10:1412-1417.
16. Yu M.W., Chang H.C., Liaw Y.F., et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. JNatl Cancer Inst 2000, 92:1159-1164.
17. Lok A.S., Lai C.L. Factors determining the development of hepatocellular carcinoma in hepatitis B surface antigen carriers. A comparison between families with clusters and solitary cases. Cancer 1988, 61:1287-1291.
18. Turati F., Edefonti V., Talamini R., et al. Family history of liver cancer and hepatocellular carcinoma. Hepatology 2012, 55:1416-1425.
19. Yang J.D., Kim W.R., Coelho R., et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011, 9:64-70.
20. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
21. Chen C.L., Yang H.I., Yang W.S., et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: afollow-up study in Taiwan. Gastroenterology 2008, 135:111-121.
22. Loomba R., Yang H.I., Su J., et al. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol 2013, 177:333-342.
23. Loomba R., Yang H.I., Su J., et al. Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men. Clin Gastroenterol Hepatol 2010, 8:891-898. e1-2.
24. Bruix J., Sherman M., American Association for the Study of Liver Diseases Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022.
25. Rothman K.J., Greenland S., Walker A.M. Concepts of interaction. Am J Epidemiol 1980, 112:467-470.
26. de Mutsert R., Jager K.J., Zoccali C., et al. The effect of joint exposures: examining the presence of interaction. Kidney Int 2009, 75:677-681.
27. Richardson D.B., Kaufman J.S. Estimation of the relative excess risk due to interaction and associated confidence bounds. Am J Epidemiol 2009, 169:756-760.
28. Volk M.L., Lok A.S. Is family history of liver cancer a risk factor for hepatocellular carcinoma?. JHepatol 2009, 50:247-248.
29. Berg A.O., Baird M.A., Botkin J.R., et al. National Institutes of Health State-of-the-Science Conference Statement: family history and improving health. Ann Intern Med 2009, 151:872-877.
30. Bravi F., Bosetti C., Negri E., et al. Family history of cancer provided by hospital controls was satisfactorily reliable. JClin Epidemiol 2007, 60:171-175.
31. Chan A.O., Yuen M.F., Lam C.M., et al. Prevalence and characteristics of familial hepatocellular carcinoma caused by chronic hepatitis B infection in Hong Kong. Aliment Pharmacol Ther 2004, 19:401-406.
32. Hassan M.M., Spitz M.R., Thomas M.B., et al. The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. JHepatol 2009, 50:334-341.
33. Donato F., Gelatti U., Chiesa R., et al. Acase-control study on family history of liver cancer as a risk factor for hepatocellular carcinoma in North Italy. Brescia HCC Study. Cancer Causes Control 1999, 10:417-421.
34. Sherman M., Bruix J., Porayko M., et al. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology 2012, 56:793-796. APGC.